康哲药业：亚甲蓝肠溶缓释片莱芙兰获批上市，预计提升结直肠病变检出率

和讯网06-18

快讯正文【康哲药业宣布，其创新药物亚甲蓝肠溶缓释片莱芙兰已获中国国家药品监督管理局批准上市】康哲药业近日公告，其研发的亚甲蓝肠溶缓释片莱芙兰，已于2024年6月11日获得中国国家药品监督管理局的上市许可。该药物主要用于增强结肠镜检查中结直肠病变的可视化，已于6月18日正式收到药品注册证书。莱芙兰采用专利的多基质(MMX)技术，确保活性物质精准输送至结肠并局部释放，有效提高病变与健康粘膜的对比度。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444310786?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-18 17:50","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2444310786","market":"hk","top_or_hot":-1,"title":"康哲药业：亚甲蓝肠溶缓释片莱芙兰获批上市，预计提升结直肠病变检出率","media":"和讯网","content":"<div>\n<p>快讯正文【康哲药业宣布，其创新药物亚甲蓝肠溶缓释片莱芙兰已获中国国家药品监督管理局批准上市】康哲药业近日公告，其研发的亚甲蓝肠溶缓释片莱芙兰，已于2024年6月11日获得中国国家药品监督管理局的上市许可。该药物主要用于增强结肠镜检查中结直肠病变的可视化，已于6月18日正式收到药品注册证书。莱芙兰采用专利的多基质(MMX)技术，确保活性物质精准输送至结肠并局部释放，有效提高病变与健康粘膜的对比度。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181811589f4a121a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业：亚甲蓝肠溶缓释片莱芙兰获批上市，预计提升结直肠病变检出率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业：亚甲蓝肠溶缓释片莱芙兰获批上市，预计提升结直肠病变检出率\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 17:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181811589f4a121a&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文【康哲药业宣布，其创新药物亚甲蓝肠溶缓释片莱芙兰已获中国国家药品监督管理局批准上市】康哲药业近日公告，其研发的亚甲蓝肠溶缓释片莱芙兰，已于2024年6月11日获得中国国家药品监督管理局的上市许可。该药物主要用于增强结肠镜检查中结直肠病变的可视化，已于6月18日正式收到药品注册证书。莱芙兰采用专利的多基质(MMX)技术，确保活性物质精准输送至结肠并局部释放，有效提高病变与健康粘膜的对比度。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181811589f4a121a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181811589f4a121a&s=b","article_id":"2444310786","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181811589f4a121a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2444310786","pubTimestamp":1718704245,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文康哲药业近日公告，其研发的亚甲蓝肠溶缓释片莱芙兰，已于2024年6月11日获得中国国家药品监督管理局的上市许可。III期临床研究结果表明，该药物能显著提升非息肉样结直肠病变的检出率，尤其是非息肉样腺瘤的检测，这对于早期结直肠癌的筛查具有重要意义。随着中国结直肠癌筛查的推广，预计肠镜检查的需求将持续增长。此外，莱芙兰已于2020年8月在欧盟获得批准，并以Lumeblue的商品名进行商业化。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","00867":"康哲药业","BK1593":"医美概念股","BK1191":"制药"},"translate_title":"China Medical System: Methylene Blue Enteric-coated Sustained-release Tablets Levlan Approved for Marketing, Expected to Increase the Detection Rate of Colorectal Diseases","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1},"content_text":"快讯正文【康哲药业宣布，其创新药物亚甲蓝肠溶缓释片莱芙兰已获中国国家药品监督管理局批准上市】康哲药业近日公告，其研发的亚甲蓝肠溶缓释片莱芙兰，已于2024年6月11日获得中国国家药品监督管理局的上市许可。该药物主要用于增强结肠镜检查中结直肠病变的可视化，已于6月18日正式收到药品注册证书。莱芙兰采用专利的多基质(MMX)技术，确保活性物质精准输送至结肠并局部释放，有效提高病变与健康粘膜的对比度。III期临床研究结果表明，该药物能显著提升非息肉样结直肠病变的检出率，尤其是非息肉样腺瘤的检测，这对于早期结直肠癌的筛查具有重要意义。随着中国结直肠癌筛查的推广，预计肠镜检查的需求将持续增长。根据中华医学会的数据，2019年全国胃肠镜检查次数已达到3873万例，较2012年增长超过34%。专家共识推荐50岁至75岁人群进行结直肠癌筛查，这一年龄段人群在2020年约为4亿。此外，莱芙兰已于2020年8月在欧盟获得批准，并以Lumeblue的商品名进行商业化。康哲药业于2020年12月从Cosmo Technologies Ltd.获得该产品的独家许可，计划有序推进其商业化进程，以期早日惠及更多结直肠病患者。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444310786"}